DrugPatentWatch Database Preview
VIIBRYD Drug Profile
» See Plans and Pricing
When do Viibryd patents expire, and when can generic versions of Viibryd launch?
Viibryd is a drug marketed by Allergan and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.
This drug has sixty patent family members in twenty-nine countries.
The generic ingredient in VIIBRYD is vilazodone hydrochloride. There are fourteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the vilazodone hydrochloride profile page.
US ANDA Litigation and Generic Entry Outlook for Viibryd
A generic version of VIIBRYD was approved as vilazodone hydrochloride by ALEMBIC PHARMS LTD on January 10th, 2020.
Summary for VIIBRYD
| International Patents: | 60 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 71 |
| Clinical Trials: | 16 |
| Patent Applications: | 37 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for VIIBRYD |
| Drug Sales Revenues: | Drug sales revenues for VIIBRYD |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VIIBRYD |
| DailyMed Link: | VIIBRYD at DailyMed |
Recent Clinical Trials for VIIBRYD
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Forest Laboratories | Phase 1 |
| New York State Psychiatric Institute | Phase 4 |
| Forest Laboratories | Phase 3 |
Paragraph IV (Patent) Challenges for VIIBRYD
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| VIIBRYD | TABLET;ORAL | vilazodone hydrochloride | 022567 | 2015-01-21 |
US Patents and Regulatory Information for VIIBRYD
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-001 | Jan 21, 2011 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||
| Allergan | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-003 | Jan 21, 2011 | AB | RX | Yes | No | Start Trial | Start Trial | Start Trial | |||
| Allergan | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-002 | Jan 21, 2011 | AB | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||
| Allergan | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-001 | Jan 21, 2011 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||
| Allergan | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-002 | Jan 21, 2011 | AB | RX | Yes | No | Start Trial | Start Trial | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VIIBRYD
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Allergan | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-001 | Jan 21, 2011 | Start Trial | Start Trial |
| Allergan | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-003 | Jan 21, 2011 | Start Trial | Start Trial |
| Allergan | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-002 | Jan 21, 2011 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VIIBRYD
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Slovakia | 162004 | Start Trial |
| Hungary | 218918 | Start Trial |
| Poland | 178137 | Start Trial |
| Slovakia | 118494 | Start Trial |
| Greece | 3024551 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
